CD274 and non-small cell lung carcinoma: Supplementing chemotherapy with PD-1/PD-L1 mAbs has significantly improved the efficacy of front-line treatment for advanced NSCLC as compared with chemotherapy alone and also demonstrated a manageable safety profile.